BLFS
BioLife Solutions, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
2.51
P/S
9.79
EV/EBITDA
-115.61
DCF Value
$-4.69
FCF Yield
1.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
64.6%
Operating Margin
-12.6%
Net Margin
-12.6%
ROE
-3.4%
ROA
-6.3%
ROIC
-3.1%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $18.8M | $3.5M | $0.08 |
| FY 2025 | $96.2M | $-12.1M | $-0.25 |
| Q3 2025 | $28.1M | $621.0K | $0.01 |
| Q2 2025 | $25.4M | $-15.8M | $-0.33 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
2.00
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.